Cubist Systematic Strategies, LLC Enanta Pharmaceuticals Inc Transaction History

Cubist Systematic Strategies, LLC

  • $15.1 Billion
  • Q4 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 20,255 shares of ENTA stock, worth $151,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,255
Previous 22,920 11.63%
Holding current value
$151,709
Previous $237,000 51.05%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$5.75 - $12.99 $15,323 - $34,618
-2,665 Reduced 11.63%
20,255 $116,000
Q3 2024

Nov 14, 2024
SELL
$10.05 - $16.54 $225,421 - $370,992
-22,430 Reduced 49.46%
22,920 $237,000
Q2 2024

Aug 14, 2024
BUY
$11.43 - $17.02 $205,774 - $306,411
18,003 Added 65.83%
45,350 $588,000
Q1 2024

May 15, 2024
SELL
$10.08 - $17.46 $558,633 - $967,633
-55,420 Reduced 66.96%
27,347 $477,000
Q4 2023

Feb 14, 2024
BUY
$8.18 - $10.78 $116,327 - $153,302
14,221 Added 20.75%
82,767 $778,000
Q3 2023

Nov 14, 2023
SELL
$11.09 - $22.13 $354,236 - $706,876
-31,942 Reduced 31.79%
68,546 $765,000
Q2 2023

Aug 14, 2023
BUY
$20.68 - $39.85 $1.33 Million - $2.56 Million
64,217 Added 177.05%
100,488 $2.15 Million
Q1 2023

May 15, 2023
BUY
$38.82 - $54.59 $56,172 - $78,991
1,447 Added 4.16%
36,271 $1.47 Million
Q4 2022

Feb 14, 2023
SELL
$40.77 - $53.73 $224,194 - $295,461
-5,499 Reduced 13.64%
34,824 $1.62 Million
Q3 2022

Nov 14, 2022
BUY
$48.29 - $71.27 $140,041 - $206,683
2,900 Added 7.75%
40,323 $2.09 Million
Q2 2022

Aug 15, 2022
BUY
$38.13 - $76.93 $1.27 Million - $2.56 Million
33,227 Added 791.87%
37,423 $1.77 Million
Q1 2022

May 16, 2022
SELL
$56.06 - $74.11 $2.39 Million - $3.16 Million
-42,655 Reduced 91.04%
4,196 $299,000
Q4 2021

Feb 14, 2022
BUY
$60.19 - $97.37 $2.13 Million - $3.45 Million
35,438 Added 310.51%
46,851 $3.5 Million
Q3 2021

Nov 15, 2021
BUY
$41.02 - $58.65 $468,161 - $669,372
11,413 New
11,413 $648,000
Q2 2021

Aug 16, 2021
SELL
$43.76 - $53.11 $178,190 - $216,263
-4,072 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$41.69 - $54.95 $169,761 - $223,756
4,072 New
4,072 $201,000
Q4 2020

Feb 16, 2021
SELL
$41.16 - $47.47 $589,246 - $679,580
-14,316 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$43.36 - $53.53 $190,653 - $235,371
4,397 Added 44.33%
14,316 $655,000
Q2 2020

Aug 14, 2020
BUY
$46.37 - $57.58 $195,264 - $242,469
4,211 Added 73.77%
9,919 $498,000
Q1 2020

May 15, 2020
SELL
$40.22 - $62.0 $93,028 - $143,406
-2,313 Reduced 28.84%
5,708 $294,000
Q4 2019

Feb 14, 2020
BUY
$57.95 - $66.61 $140,992 - $162,062
2,433 Added 43.54%
8,021 $496,000
Q3 2019

Nov 14, 2019
BUY
$60.08 - $88.17 $41,154 - $60,396
685 Added 13.97%
5,588 $336,000
Q2 2019

Aug 14, 2019
BUY
$81.3 - $97.35 $95,527 - $114,386
1,175 Added 31.52%
4,903 $414,000
Q1 2019

May 15, 2019
BUY
$69.08 - $105.66 $28,115 - $43,003
407 Added 12.26%
3,728 $356,000
Q4 2018

Feb 14, 2019
BUY
$65.41 - $84.65 $217,226 - $281,122
3,321 New
3,321 $235,000
Q3 2018

Nov 14, 2018
SELL
$85.46 - $126.37 $398,329 - $589,010
-4,661 Closed
0 $0
Q2 2018

Aug 14, 2018
SELL
$81.85 - $120.51 $97,319 - $143,286
-1,189 Reduced 20.32%
4,661 $540,000
Q1 2018

May 15, 2018
BUY
$57.91 - $92.15 $71,982 - $114,542
1,243 Added 26.98%
5,850 $473,000
Q4 2017

Feb 14, 2018
BUY
$45.65 - $59.37 $210,309 - $273,517
4,607
4,607 $270,000

Others Institutions Holding ENTA

# of Institutions
108
Shares Held
19.7M
Call Options Held
9.7K
Put Options Held
12.4K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $155M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email